Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Growth 2024-2030
The report requires updating with new data and is sent in 48 hours after order is placed.
According to our LPI (LP Information) latest study, the global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs market size was valued at US$ 1357.9 million in 2023. With growing demand in downstream market, the Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs is forecast to a readjusted size of US$ 2837 million by 2030 with a CAGR of 11.1% during review period.
The research report highlights the growth potential of the global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs market. Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs are expected to show stable growth in the future market. However, product differentiation, reducing costs, and supply chain optimization remain crucial for the widespread adoption of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs. Market players need to invest in research and development, forge strategic partnerships, and align their offerings with evolving consumer preferences to capitalize on the immense opportunities presented by the Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs market.
Irritable bowel syndrome (IBS) is a common disorder that affects the large intestine. Signs and symptoms include cramping, abdominal pain, bloating, gas, and diarrhea or constipation, or both. IBS is a chronic condition that need to manage long term.
IBS that causes increased diarrhea is often called IBS-D. Diarrhea predominant irritable bowel syndrome (IBS-D) is a subtype of IBS in which a person experiences frequent episodes of diarrhea with accompanying abdominal pain. Like IBS, IBS-D is a functional gastrointestinal disorder (FGD) in that there is no visible disease, inflammation, or injury to account for its symptoms. It is estimated that approximately a third of people who have IBS experience the disorder with diarrhea as the predominant bowel habit.
In this report, we study the drugs for diarrhea predominant irritable bowel syndrome (IBS-D).
North America is the largest consumption place of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs, followed by Europe. The two account for more than 80% of the consumer market in together. The most used IBS-D drug is XIFAXAN, accounting for more than 60% of the market share, followed by Viberzi and Lotronex. IBS-D drugs are widely sold through hospital pharmacies and retail pharmacies.
Key Features:
The report on Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs market reflects various aspects and provide valuable insights into the industry.
Market Size and Growth: The research report provide an overview of the current size and growth of the Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs market. It may include historical data, market segmentation by Type (e.g., XIFAXAN, Viberzi), and regional breakdowns.
Market Drivers and Challenges: The report can identify and analyse the factors driving the growth of the Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs market, such as government regulations, environmental concerns, technological advancements, and changing consumer preferences. It can also highlight the challenges faced by the industry, including infrastructure limitations, range anxiety, and high upfront costs.
Competitive Landscape: The research report provides analysis of the competitive landscape within the Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs market. It includes profiles of key players, their market share, strategies, and product offerings. The report can also highlight emerging players and their potential impact on the market.
Technological Developments: The research report can delve into the latest technological developments in the Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs industry. This include advancements in Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs technology, Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs new entrants, Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs new investment, and other innovations that are shaping the future of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs.
Downstream Procumbent Preference: The report can shed light on customer procumbent behaviour and adoption trends in the Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs market. It includes factors influencing customer ' purchasing decisions, preferences for Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs product.
Government Policies and Incentives: The research report analyse the impact of government policies and incentives on the Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs market. This may include an assessment of regulatory frameworks, subsidies, tax incentives, and other measures aimed at promoting Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs market. The report also evaluates the effectiveness of these policies in driving market growth.
Environmental Impact and Sustainability: The research report assess the environmental impact and sustainability aspects of the Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs market.
Market Forecasts and Future Outlook: Based on the analysis conducted, the research report provide market forecasts and outlook for the Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs industry. This includes projections of market size, growth rates, regional trends, and predictions on technological advancements and policy developments.
Recommendations and Opportunities: The report conclude with recommendations for industry stakeholders, policymakers, and investors. It highlights potential opportunities for market players to capitalize on emerging trends, overcome challenges, and contribute to the growth and development of the Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs market.
Market Segmentation:
Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs market is split by Type and by Sales Channel. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Sales Channel in terms of volume and value.
Segmentation by type
What is the 10-year outlook for the global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs market?
What factors are driving Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs market opportunities vary by end market size?
How does Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs break out type, sales channel?
According to our LPI (LP Information) latest study, the global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs market size was valued at US$ 1357.9 million in 2023. With growing demand in downstream market, the Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs is forecast to a readjusted size of US$ 2837 million by 2030 with a CAGR of 11.1% during review period.
The research report highlights the growth potential of the global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs market. Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs are expected to show stable growth in the future market. However, product differentiation, reducing costs, and supply chain optimization remain crucial for the widespread adoption of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs. Market players need to invest in research and development, forge strategic partnerships, and align their offerings with evolving consumer preferences to capitalize on the immense opportunities presented by the Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs market.
Irritable bowel syndrome (IBS) is a common disorder that affects the large intestine. Signs and symptoms include cramping, abdominal pain, bloating, gas, and diarrhea or constipation, or both. IBS is a chronic condition that need to manage long term.
IBS that causes increased diarrhea is often called IBS-D. Diarrhea predominant irritable bowel syndrome (IBS-D) is a subtype of IBS in which a person experiences frequent episodes of diarrhea with accompanying abdominal pain. Like IBS, IBS-D is a functional gastrointestinal disorder (FGD) in that there is no visible disease, inflammation, or injury to account for its symptoms. It is estimated that approximately a third of people who have IBS experience the disorder with diarrhea as the predominant bowel habit.
In this report, we study the drugs for diarrhea predominant irritable bowel syndrome (IBS-D).
North America is the largest consumption place of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs, followed by Europe. The two account for more than 80% of the consumer market in together. The most used IBS-D drug is XIFAXAN, accounting for more than 60% of the market share, followed by Viberzi and Lotronex. IBS-D drugs are widely sold through hospital pharmacies and retail pharmacies.
Key Features:
The report on Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs market reflects various aspects and provide valuable insights into the industry.
Market Size and Growth: The research report provide an overview of the current size and growth of the Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs market. It may include historical data, market segmentation by Type (e.g., XIFAXAN, Viberzi), and regional breakdowns.
Market Drivers and Challenges: The report can identify and analyse the factors driving the growth of the Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs market, such as government regulations, environmental concerns, technological advancements, and changing consumer preferences. It can also highlight the challenges faced by the industry, including infrastructure limitations, range anxiety, and high upfront costs.
Competitive Landscape: The research report provides analysis of the competitive landscape within the Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs market. It includes profiles of key players, their market share, strategies, and product offerings. The report can also highlight emerging players and their potential impact on the market.
Technological Developments: The research report can delve into the latest technological developments in the Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs industry. This include advancements in Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs technology, Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs new entrants, Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs new investment, and other innovations that are shaping the future of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs.
Downstream Procumbent Preference: The report can shed light on customer procumbent behaviour and adoption trends in the Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs market. It includes factors influencing customer ' purchasing decisions, preferences for Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs product.
Government Policies and Incentives: The research report analyse the impact of government policies and incentives on the Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs market. This may include an assessment of regulatory frameworks, subsidies, tax incentives, and other measures aimed at promoting Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs market. The report also evaluates the effectiveness of these policies in driving market growth.
Environmental Impact and Sustainability: The research report assess the environmental impact and sustainability aspects of the Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs market.
Market Forecasts and Future Outlook: Based on the analysis conducted, the research report provide market forecasts and outlook for the Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs industry. This includes projections of market size, growth rates, regional trends, and predictions on technological advancements and policy developments.
Recommendations and Opportunities: The report conclude with recommendations for industry stakeholders, policymakers, and investors. It highlights potential opportunities for market players to capitalize on emerging trends, overcome challenges, and contribute to the growth and development of the Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs market.
Market Segmentation:
Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs market is split by Type and by Sales Channel. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Sales Channel in terms of volume and value.
Segmentation by type
- XIFAXAN
- Viberzi
- Lotronex
- Other
- Hospitals Pharmacy
- Retail Pharmacy
- Other
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- Bausch Health
- Allergan
- Sebela Pharmaceuticals
- Astellas Pharmaceuticals
- Amneal Pharms
- Pharscin Pharma
What is the 10-year outlook for the global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs market?
What factors are driving Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs market opportunities vary by end market size?
How does Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs break out type, sales channel?
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Annual Sales 2019-2030
2.1.2 World Current & Future Analysis for Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs by Geographic Region, 2019, 2023 & 2030
2.1.3 World Current & Future Analysis for Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs by Country/Region, 2019, 2023 & 2030
2.2 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Segment by Type
2.2.1 XIFAXAN
2.2.2 Viberzi
2.2.3 Lotronex
2.2.4 Other
2.3 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Type
2.3.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Type (2019-2024)
2.3.2 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue and Market Share by Type (2019-2024)
2.3.3 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sale Price by Type (2019-2024)
2.4 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Segment by Sales Channel
2.4.1 Hospitals Pharmacy
2.4.2 Retail Pharmacy
2.4.3 Other
2.5 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Sales Channel
2.5.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sale Market Share by Sales Channel (2019-2024)
2.5.2 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue and Market Share by Sales Channel (2019-2024)
2.5.3 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sale Price by Sales Channel (2019-2024)
3 GLOBAL IRRITABLE BOWEL SYNDROME WITH DIARRHEA (IBS-D) DRUGS BY COMPANY
3.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Breakdown Data by Company
3.1.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Annual Sales by Company (2019-2024)
3.1.2 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Company (2019-2024)
3.2 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Annual Revenue by Company (2019-2024)
3.2.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Company (2019-2024)
3.2.2 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Market Share by Company (2019-2024)
3.3 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sale Price by Company
3.4 Key Manufacturers Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product Location Distribution
3.4.2 Players Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2019-2024)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 WORLD HISTORIC REVIEW FOR IRRITABLE BOWEL SYNDROME WITH DIARRHEA (IBS-D) DRUGS BY GEOGRAPHIC REGION
4.1 World Historic Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Size by Geographic Region (2019-2024)
4.1.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Annual Sales by Geographic Region (2019-2024)
4.1.2 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Annual Revenue by Geographic Region (2019-2024)
4.2 World Historic Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Size by Country/Region (2019-2024)
4.2.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Annual Sales by Country/Region (2019-2024)
4.2.2 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Annual Revenue by Country/Region (2019-2024)
4.3 Americas Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Growth
4.4 APAC Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Growth
4.5 Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Growth
4.6 Middle East & Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Growth
5 AMERICAS
5.1 Americas Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Country
5.1.1 Americas Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Country (2019-2024)
5.1.2 Americas Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Country (2019-2024)
5.2 Americas Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Type
5.3 Americas Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Sales Channel
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Region
6.1.1 APAC Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Region (2019-2024)
6.1.2 APAC Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Region (2019-2024)
6.2 APAC Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Type
6.3 APAC Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Sales Channel
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs by Country
7.1.1 Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Country (2019-2024)
7.1.2 Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Country (2019-2024)
7.2 Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Type
7.3 Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Sales Channel
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs by Country
8.1.1 Middle East & Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Country (2019-2024)
8.1.2 Middle East & Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Country (2019-2024)
8.2 Middle East & Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Type
8.3 Middle East & Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Sales Channel
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs
10.3 Manufacturing Process Analysis of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs
10.4 Industry Chain Structure of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Distributors
11.3 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Customer
12 WORLD FORECAST REVIEW FOR IRRITABLE BOWEL SYNDROME WITH DIARRHEA (IBS-D) DRUGS BY GEOGRAPHIC REGION
12.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Size Forecast by Region
12.1.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Forecast by Region (2025-2030)
12.1.2 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Annual Revenue Forecast by Region (2025-2030)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Forecast by Type
12.7 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Forecast by Sales Channel
13 KEY PLAYERS ANALYSIS
13.1 Bausch Health
13.1.1 Bausch Health Company Information
13.1.2 Bausch Health Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product Portfolios and Specifications
13.1.3 Bausch Health Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
13.1.4 Bausch Health Main Business Overview
13.1.5 Bausch Health Latest Developments
13.2 Allergan
13.2.1 Allergan Company Information
13.2.2 Allergan Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product Portfolios and Specifications
13.2.3 Allergan Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
13.2.4 Allergan Main Business Overview
13.2.5 Allergan Latest Developments
13.3 Sebela Pharmaceuticals
13.3.1 Sebela Pharmaceuticals Company Information
13.3.2 Sebela Pharmaceuticals Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product Portfolios and Specifications
13.3.3 Sebela Pharmaceuticals Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
13.3.4 Sebela Pharmaceuticals Main Business Overview
13.3.5 Sebela Pharmaceuticals Latest Developments
13.4 Astellas Pharmaceuticals
13.4.1 Astellas Pharmaceuticals Company Information
13.4.2 Astellas Pharmaceuticals Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product Portfolios and Specifications
13.4.3 Astellas Pharmaceuticals Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
13.4.4 Astellas Pharmaceuticals Main Business Overview
13.4.5 Astellas Pharmaceuticals Latest Developments
13.5 Amneal Pharms
13.5.1 Amneal Pharms Company Information
13.5.2 Amneal Pharms Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product Portfolios and Specifications
13.5.3 Amneal Pharms Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
13.5.4 Amneal Pharms Main Business Overview
13.5.5 Amneal Pharms Latest Developments
13.6 Pharscin Pharma
13.6.1 Pharscin Pharma Company Information
13.6.2 Pharscin Pharma Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product Portfolios and Specifications
13.6.3 Pharscin Pharma Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
13.6.4 Pharscin Pharma Main Business Overview
13.6.5 Pharscin Pharma Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Annual Sales 2019-2030
2.1.2 World Current & Future Analysis for Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs by Geographic Region, 2019, 2023 & 2030
2.1.3 World Current & Future Analysis for Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs by Country/Region, 2019, 2023 & 2030
2.2 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Segment by Type
2.2.1 XIFAXAN
2.2.2 Viberzi
2.2.3 Lotronex
2.2.4 Other
2.3 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Type
2.3.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Type (2019-2024)
2.3.2 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue and Market Share by Type (2019-2024)
2.3.3 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sale Price by Type (2019-2024)
2.4 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Segment by Sales Channel
2.4.1 Hospitals Pharmacy
2.4.2 Retail Pharmacy
2.4.3 Other
2.5 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Sales Channel
2.5.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sale Market Share by Sales Channel (2019-2024)
2.5.2 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue and Market Share by Sales Channel (2019-2024)
2.5.3 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sale Price by Sales Channel (2019-2024)
3 GLOBAL IRRITABLE BOWEL SYNDROME WITH DIARRHEA (IBS-D) DRUGS BY COMPANY
3.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Breakdown Data by Company
3.1.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Annual Sales by Company (2019-2024)
3.1.2 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Company (2019-2024)
3.2 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Annual Revenue by Company (2019-2024)
3.2.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Company (2019-2024)
3.2.2 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Market Share by Company (2019-2024)
3.3 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sale Price by Company
3.4 Key Manufacturers Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product Location Distribution
3.4.2 Players Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2019-2024)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 WORLD HISTORIC REVIEW FOR IRRITABLE BOWEL SYNDROME WITH DIARRHEA (IBS-D) DRUGS BY GEOGRAPHIC REGION
4.1 World Historic Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Size by Geographic Region (2019-2024)
4.1.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Annual Sales by Geographic Region (2019-2024)
4.1.2 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Annual Revenue by Geographic Region (2019-2024)
4.2 World Historic Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Size by Country/Region (2019-2024)
4.2.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Annual Sales by Country/Region (2019-2024)
4.2.2 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Annual Revenue by Country/Region (2019-2024)
4.3 Americas Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Growth
4.4 APAC Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Growth
4.5 Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Growth
4.6 Middle East & Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Growth
5 AMERICAS
5.1 Americas Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Country
5.1.1 Americas Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Country (2019-2024)
5.1.2 Americas Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Country (2019-2024)
5.2 Americas Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Type
5.3 Americas Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Sales Channel
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Region
6.1.1 APAC Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Region (2019-2024)
6.1.2 APAC Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Region (2019-2024)
6.2 APAC Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Type
6.3 APAC Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Sales Channel
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs by Country
7.1.1 Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Country (2019-2024)
7.1.2 Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Country (2019-2024)
7.2 Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Type
7.3 Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Sales Channel
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs by Country
8.1.1 Middle East & Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Country (2019-2024)
8.1.2 Middle East & Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Country (2019-2024)
8.2 Middle East & Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Type
8.3 Middle East & Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Sales Channel
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs
10.3 Manufacturing Process Analysis of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs
10.4 Industry Chain Structure of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Distributors
11.3 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Customer
12 WORLD FORECAST REVIEW FOR IRRITABLE BOWEL SYNDROME WITH DIARRHEA (IBS-D) DRUGS BY GEOGRAPHIC REGION
12.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Size Forecast by Region
12.1.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Forecast by Region (2025-2030)
12.1.2 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Annual Revenue Forecast by Region (2025-2030)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Forecast by Type
12.7 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Forecast by Sales Channel
13 KEY PLAYERS ANALYSIS
13.1 Bausch Health
13.1.1 Bausch Health Company Information
13.1.2 Bausch Health Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product Portfolios and Specifications
13.1.3 Bausch Health Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
13.1.4 Bausch Health Main Business Overview
13.1.5 Bausch Health Latest Developments
13.2 Allergan
13.2.1 Allergan Company Information
13.2.2 Allergan Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product Portfolios and Specifications
13.2.3 Allergan Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
13.2.4 Allergan Main Business Overview
13.2.5 Allergan Latest Developments
13.3 Sebela Pharmaceuticals
13.3.1 Sebela Pharmaceuticals Company Information
13.3.2 Sebela Pharmaceuticals Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product Portfolios and Specifications
13.3.3 Sebela Pharmaceuticals Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
13.3.4 Sebela Pharmaceuticals Main Business Overview
13.3.5 Sebela Pharmaceuticals Latest Developments
13.4 Astellas Pharmaceuticals
13.4.1 Astellas Pharmaceuticals Company Information
13.4.2 Astellas Pharmaceuticals Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product Portfolios and Specifications
13.4.3 Astellas Pharmaceuticals Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
13.4.4 Astellas Pharmaceuticals Main Business Overview
13.4.5 Astellas Pharmaceuticals Latest Developments
13.5 Amneal Pharms
13.5.1 Amneal Pharms Company Information
13.5.2 Amneal Pharms Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product Portfolios and Specifications
13.5.3 Amneal Pharms Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
13.5.4 Amneal Pharms Main Business Overview
13.5.5 Amneal Pharms Latest Developments
13.6 Pharscin Pharma
13.6.1 Pharscin Pharma Company Information
13.6.2 Pharscin Pharma Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product Portfolios and Specifications
13.6.3 Pharscin Pharma Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
13.6.4 Pharscin Pharma Main Business Overview
13.6.5 Pharscin Pharma Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
LIST OF TABLES
Table 1. Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Annual Sales CAGR by Geographic Region (2019, 2023 & 2030) & ($ millions)
Table 2. Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Annual Sales CAGR by Country/Region (2019, 2023 & 2030) & ($ millions)
Table 3. Major Players of XIFAXAN
Table 4. Major Players of Viberzi
Table 5. Major Players of Lotronex
Table 6. Major Players of Other
Table 7. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Type (2019-2024) & (K Units)
Table 8. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Type (2019-2024)
Table 9. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Type (2019-2024) & ($ million)
Table 10. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Market Share by Type (2019-2024)
Table 11. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sale Price by Type (2019-2024) & (USD/Unit)
Table 12. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Sales Channel (2019-2024) & (K Units)
Table 13. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Sales Channel (2019-2024)
Table 14. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Sales Channel (2019-2024)
Table 15. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Market Share by Sales Channel (2019-2024)
Table 16. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sale Price by Sales Channel (2019-2024) & (USD/Unit)
Table 17. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Company (2019-2024) & (K Units)
Table 18. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Company (2019-2024)
Table 19. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Company (2019-2024) ($ Millions)
Table 20. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Market Share by Company (2019-2024)
Table 21. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sale Price by Company (2019-2024) & (USD/Unit)
Table 22. Key Manufacturers Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Producing Area Distribution and Sales Area
Table 23. Players Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Products Offered
Table 24. Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Concentration Ratio (CR3, CR5 and CR10) & (2019-2024)
Table 25. New Products and Potential Entrants
Table 26. Mergers & Acquisitions, Expansion
Table 27. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Geographic Region (2019-2024) & (K Units)
Table 28. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share Geographic Region (2019-2024)
Table 29. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Geographic Region (2019-2024) & ($ millions)
Table 30. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Market Share by Geographic Region (2019-2024)
Table 31. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Country/Region (2019-2024) & (K Units)
Table 32. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Country/Region (2019-2024)
Table 33. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Country/Region (2019-2024) & ($ millions)
Table 34. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Market Share by Country/Region (2019-2024)
Table 35. Americas Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Country (2019-2024) & (K Units)
Table 36. Americas Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Country (2019-2024)
Table 37. Americas Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Country (2019-2024) & ($ Millions)
Table 38. Americas Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Market Share by Country (2019-2024)
Table 39. Americas Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Type (2019-2024) & (K Units)
Table 40. Americas Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Sales Channel (2019-2024) & (K Units)
Table 41. APAC Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Region (2019-2024) & (K Units)
Table 42. APAC Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Region (2019-2024)
Table 43. APAC Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Region (2019-2024) & ($ Millions)
Table 44. APAC Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Market Share by Region (2019-2024)
Table 45. APAC Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Type (2019-2024) & (K Units)
Table 46. APAC Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Sales Channel (2019-2024) & (K Units)
Table 47. Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Country (2019-2024) & (K Units)
Table 48. Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Country (2019-2024)
Table 49. Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Country (2019-2024) & ($ Millions)
Table 50. Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Market Share by Country (2019-2024)
Table 51. Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Type (2019-2024) & (K Units)
Table 52. Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Sales Channel (2019-2024) & (K Units)
Table 53. Middle East & Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Country (2019-2024) & (K Units)
Table 54. Middle East & Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Country (2019-2024)
Table 55. Middle East & Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Country (2019-2024) & ($ Millions)
Table 56. Middle East & Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Market Share by Country (2019-2024)
Table 57. Middle East & Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Type (2019-2024) & (K Units)
Table 58. Middle East & Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Sales Channel (2019-2024) & (K Units)
Table 59. Key Market Drivers & Growth Opportunities of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs
Table 60. Key Market Challenges & Risks of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs
Table 61. Key Industry Trends of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs
Table 62. Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Raw Material
Table 63. Key Suppliers of Raw Materials
Table 64. Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Distributors List
Table 65. Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Customer List
Table 66. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Forecast by Region (2025-2030) & (K Units)
Table 67. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Forecast by Region (2025-2030) & ($ millions)
Table 68. Americas Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Forecast by Country (2025-2030) & (K Units)
Table 69. Americas Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Forecast by Country (2025-2030) & ($ millions)
Table 70. APAC Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Forecast by Region (2025-2030) & (K Units)
Table 71. APAC Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Forecast by Region (2025-2030) & ($ millions)
Table 72. Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Forecast by Country (2025-2030) & (K Units)
Table 73. Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Forecast by Country (2025-2030) & ($ millions)
Table 74. Middle East & Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Forecast by Country (2025-2030) & (K Units)
Table 75. Middle East & Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Forecast by Country (2025-2030) & ($ millions)
Table 76. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Forecast by Type (2025-2030) & (K Units)
Table 77. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Forecast by Type (2025-2030) & ($ Millions)
Table 78. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Forecast by Sales Channel (2025-2030) & (K Units)
Table 79. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Forecast by Sales Channel (2025-2030) & ($ Millions)
Table 80. Bausch Health Basic Information, Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Manufacturing Base, Sales Area and Its Competitors
Table 81. Bausch Health Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product Portfolios and Specifications
Table 82. Bausch Health Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 83. Bausch Health Main Business
Table 84. Bausch Health Latest Developments
Table 85. Allergan Basic Information, Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Manufacturing Base, Sales Area and Its Competitors
Table 86. Allergan Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product Portfolios and Specifications
Table 87. Allergan Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 88. Allergan Main Business
Table 89. Allergan Latest Developments
Table 90. Sebela Pharmaceuticals Basic Information, Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Manufacturing Base, Sales Area and Its Competitors
Table 91. Sebela Pharmaceuticals Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product Portfolios and Specifications
Table 92. Sebela Pharmaceuticals Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 93. Sebela Pharmaceuticals Main Business
Table 94. Sebela Pharmaceuticals Latest Developments
Table 95. Astellas Pharmaceuticals Basic Information, Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Manufacturing Base, Sales Area and Its Competitors
Table 96. Astellas Pharmaceuticals Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product Portfolios and Specifications
Table 97. Astellas Pharmaceuticals Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 98. Astellas Pharmaceuticals Main Business
Table 99. Astellas Pharmaceuticals Latest Developments
Table 100. Amneal Pharms Basic Information, Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Manufacturing Base, Sales Area and Its Competitors
Table 101. Amneal Pharms Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product Portfolios and Specifications
Table 102. Amneal Pharms Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 103. Amneal Pharms Main Business
Table 104. Amneal Pharms Latest Developments
Table 105. Pharscin Pharma Basic Information, Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Manufacturing Base, Sales Area and Its Competitors
Table 106. Pharscin Pharma Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product Portfolios and Specifications
Table 107. Pharscin Pharma Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 108. Pharscin Pharma Main Business
Table 109. Pharscin Pharma Latest Developments
Table 1. Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Annual Sales CAGR by Geographic Region (2019, 2023 & 2030) & ($ millions)
Table 2. Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Annual Sales CAGR by Country/Region (2019, 2023 & 2030) & ($ millions)
Table 3. Major Players of XIFAXAN
Table 4. Major Players of Viberzi
Table 5. Major Players of Lotronex
Table 6. Major Players of Other
Table 7. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Type (2019-2024) & (K Units)
Table 8. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Type (2019-2024)
Table 9. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Type (2019-2024) & ($ million)
Table 10. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Market Share by Type (2019-2024)
Table 11. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sale Price by Type (2019-2024) & (USD/Unit)
Table 12. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Sales Channel (2019-2024) & (K Units)
Table 13. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Sales Channel (2019-2024)
Table 14. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Sales Channel (2019-2024)
Table 15. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Market Share by Sales Channel (2019-2024)
Table 16. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sale Price by Sales Channel (2019-2024) & (USD/Unit)
Table 17. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Company (2019-2024) & (K Units)
Table 18. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Company (2019-2024)
Table 19. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Company (2019-2024) ($ Millions)
Table 20. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Market Share by Company (2019-2024)
Table 21. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sale Price by Company (2019-2024) & (USD/Unit)
Table 22. Key Manufacturers Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Producing Area Distribution and Sales Area
Table 23. Players Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Products Offered
Table 24. Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Concentration Ratio (CR3, CR5 and CR10) & (2019-2024)
Table 25. New Products and Potential Entrants
Table 26. Mergers & Acquisitions, Expansion
Table 27. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Geographic Region (2019-2024) & (K Units)
Table 28. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share Geographic Region (2019-2024)
Table 29. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Geographic Region (2019-2024) & ($ millions)
Table 30. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Market Share by Geographic Region (2019-2024)
Table 31. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Country/Region (2019-2024) & (K Units)
Table 32. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Country/Region (2019-2024)
Table 33. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Country/Region (2019-2024) & ($ millions)
Table 34. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Market Share by Country/Region (2019-2024)
Table 35. Americas Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Country (2019-2024) & (K Units)
Table 36. Americas Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Country (2019-2024)
Table 37. Americas Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Country (2019-2024) & ($ Millions)
Table 38. Americas Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Market Share by Country (2019-2024)
Table 39. Americas Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Type (2019-2024) & (K Units)
Table 40. Americas Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Sales Channel (2019-2024) & (K Units)
Table 41. APAC Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Region (2019-2024) & (K Units)
Table 42. APAC Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Region (2019-2024)
Table 43. APAC Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Region (2019-2024) & ($ Millions)
Table 44. APAC Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Market Share by Region (2019-2024)
Table 45. APAC Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Type (2019-2024) & (K Units)
Table 46. APAC Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Sales Channel (2019-2024) & (K Units)
Table 47. Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Country (2019-2024) & (K Units)
Table 48. Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Country (2019-2024)
Table 49. Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Country (2019-2024) & ($ Millions)
Table 50. Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Market Share by Country (2019-2024)
Table 51. Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Type (2019-2024) & (K Units)
Table 52. Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Sales Channel (2019-2024) & (K Units)
Table 53. Middle East & Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Country (2019-2024) & (K Units)
Table 54. Middle East & Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Country (2019-2024)
Table 55. Middle East & Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Country (2019-2024) & ($ Millions)
Table 56. Middle East & Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Market Share by Country (2019-2024)
Table 57. Middle East & Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Type (2019-2024) & (K Units)
Table 58. Middle East & Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Sales Channel (2019-2024) & (K Units)
Table 59. Key Market Drivers & Growth Opportunities of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs
Table 60. Key Market Challenges & Risks of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs
Table 61. Key Industry Trends of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs
Table 62. Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Raw Material
Table 63. Key Suppliers of Raw Materials
Table 64. Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Distributors List
Table 65. Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Customer List
Table 66. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Forecast by Region (2025-2030) & (K Units)
Table 67. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Forecast by Region (2025-2030) & ($ millions)
Table 68. Americas Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Forecast by Country (2025-2030) & (K Units)
Table 69. Americas Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Forecast by Country (2025-2030) & ($ millions)
Table 70. APAC Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Forecast by Region (2025-2030) & (K Units)
Table 71. APAC Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Forecast by Region (2025-2030) & ($ millions)
Table 72. Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Forecast by Country (2025-2030) & (K Units)
Table 73. Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Forecast by Country (2025-2030) & ($ millions)
Table 74. Middle East & Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Forecast by Country (2025-2030) & (K Units)
Table 75. Middle East & Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Forecast by Country (2025-2030) & ($ millions)
Table 76. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Forecast by Type (2025-2030) & (K Units)
Table 77. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Forecast by Type (2025-2030) & ($ Millions)
Table 78. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Forecast by Sales Channel (2025-2030) & (K Units)
Table 79. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Forecast by Sales Channel (2025-2030) & ($ Millions)
Table 80. Bausch Health Basic Information, Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Manufacturing Base, Sales Area and Its Competitors
Table 81. Bausch Health Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product Portfolios and Specifications
Table 82. Bausch Health Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 83. Bausch Health Main Business
Table 84. Bausch Health Latest Developments
Table 85. Allergan Basic Information, Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Manufacturing Base, Sales Area and Its Competitors
Table 86. Allergan Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product Portfolios and Specifications
Table 87. Allergan Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 88. Allergan Main Business
Table 89. Allergan Latest Developments
Table 90. Sebela Pharmaceuticals Basic Information, Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Manufacturing Base, Sales Area and Its Competitors
Table 91. Sebela Pharmaceuticals Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product Portfolios and Specifications
Table 92. Sebela Pharmaceuticals Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 93. Sebela Pharmaceuticals Main Business
Table 94. Sebela Pharmaceuticals Latest Developments
Table 95. Astellas Pharmaceuticals Basic Information, Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Manufacturing Base, Sales Area and Its Competitors
Table 96. Astellas Pharmaceuticals Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product Portfolios and Specifications
Table 97. Astellas Pharmaceuticals Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 98. Astellas Pharmaceuticals Main Business
Table 99. Astellas Pharmaceuticals Latest Developments
Table 100. Amneal Pharms Basic Information, Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Manufacturing Base, Sales Area and Its Competitors
Table 101. Amneal Pharms Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product Portfolios and Specifications
Table 102. Amneal Pharms Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 103. Amneal Pharms Main Business
Table 104. Amneal Pharms Latest Developments
Table 105. Pharscin Pharma Basic Information, Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Manufacturing Base, Sales Area and Its Competitors
Table 106. Pharscin Pharma Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product Portfolios and Specifications
Table 107. Pharscin Pharma Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 108. Pharscin Pharma Main Business
Table 109. Pharscin Pharma Latest Developments
LIST OF FIGURES
Figure 1. Picture of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs
Figure 2. Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Growth Rate 2019-2030 (K Units)
Figure 7. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Growth Rate 2019-2030 ($ Millions)
Figure 8. Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Region (2019, 2023 & 2030) & ($ Millions)
Figure 9. Product Picture of XIFAXAN
Figure 10. Product Picture of Viberzi
Figure 11. Product Picture of Lotronex
Figure 12. Product Picture of Other
Figure 13. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Type in 2023
Figure 14. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Market Share by Type (2019-2024)
Figure 15. Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumed in Hospitals Pharmacy
Figure 16. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market: Hospitals Pharmacy (2019-2024) & (K Units)
Figure 17. Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumed in Retail Pharmacy
Figure 18. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market: Retail Pharmacy (2019-2024) & (K Units)
Figure 19. Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumed in Other
Figure 20. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market: Other (2019-2024) & (K Units)
Figure 21. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Sales Channel (2023)
Figure 22. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Market Share by Sales Channel in 2023
Figure 23. Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market by Company in 2023 (K Units)
Figure 24. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Company in 2023
Figure 25. Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Market by Company in 2023 ($ Million)
Figure 26. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Market Share by Company in 2023
Figure 27. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Geographic Region (2019-2024)
Figure 28. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Market Share by Geographic Region in 2023
Figure 29. Americas Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales 2019-2024 (K Units)
Figure 30. Americas Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue 2019-2024 ($ Millions)
Figure 31. APAC Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales 2019-2024 (K Units)
Figure 32. APAC Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue 2019-2024 ($ Millions)
Figure 33. Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales 2019-2024 (K Units)
Figure 34. Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue 2019-2024 ($ Millions)
Figure 35. Middle East & Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales 2019-2024 (K Units)
Figure 36. Middle East & Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue 2019-2024 ($ Millions)
Figure 37. Americas Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Country in 2023
Figure 38. Americas Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Market Share by Country in 2023
Figure 39. Americas Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Type (2019-2024)
Figure 40. Americas Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Sales Channel (2019-2024)
Figure 41. United States Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Growth 2019-2024 ($ Millions)
Figure 42. Canada Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Growth 2019-2024 ($ Millions)
Figure 43. Mexico Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Growth 2019-2024 ($ Millions)
Figure 44. Brazil Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Growth 2019-2024 ($ Millions)
Figure 45. APAC Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Region in 2023
Figure 46. APAC Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Market Share by Regions in 2023
Figure 47. APAC Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Type (2019-2024)
Figure 48. APAC Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Sales Channel (2019-2024)
Figure 49. China Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Growth 2019-2024 ($ Millions)
Figure 50. Japan Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Growth 2019-2024 ($ Millions)
Figure 51. South Korea Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Growth 2019-2024 ($ Millions)
Figure 52. Southeast Asia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Growth 2019-2024 ($ Millions)
Figure 53. India Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Growth 2019-2024 ($ Millions)
Figure 54. Australia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Growth 2019-2024 ($ Millions)
Figure 55. China Taiwan Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Growth 2019-2024 ($ Millions)
Figure 56. Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Country in 2023
Figure 57. Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Market Share by Country in 2023
Figure 58. Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Type (2019-2024)
Figure 59. Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Sales Channel (2019-2024)
Figure 60. Germany Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Growth 2019-2024 ($ Millions)
Figure 61. France Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Growth 2019-2024 ($ Millions)
Figure 62. UK Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Growth 2019-2024 ($ Millions)
Figure 63. Italy Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Growth 2019-2024 ($ Millions)
Figure 64. Russia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Growth 2019-2024 ($ Millions)
Figure 65. Middle East & Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Country in 2023
Figure 66. Middle East & Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Market Share by Country in 2023
Figure 67. Middle East & Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Type (2019-2024)
Figure 68. Middle East & Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Sales Channel (2019-2024)
Figure 69. Egypt Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Growth 2019-2024 ($ Millions)
Figure 70. South Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Growth 2019-2024 ($ Millions)
Figure 71. Israel Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Growth 2019-2024 ($ Millions)
Figure 72. Turkey Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Growth 2019-2024 ($ Millions)
Figure 73. GCC Country Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Growth 2019-2024 ($ Millions)
Figure 74. Manufacturing Cost Structure Analysis of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs in 2023
Figure 75. Manufacturing Process Analysis of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs
Figure 76. Industry Chain Structure of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs
Figure 77. Channels of Distribution
Figure 78. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Forecast by Region (2025-2030)
Figure 79. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Market Share Forecast by Region (2025-2030)
Figure 80. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share Forecast by Type (2025-2030)
Figure 81. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Market Share Forecast by Type (2025-2030)
Figure 82. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share Forecast by Sales Channel (2025-2030)
Figure 83. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Market Share Forecast by Sales Channel (2025-2030)
Figure 1. Picture of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs
Figure 2. Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Growth Rate 2019-2030 (K Units)
Figure 7. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Growth Rate 2019-2030 ($ Millions)
Figure 8. Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Region (2019, 2023 & 2030) & ($ Millions)
Figure 9. Product Picture of XIFAXAN
Figure 10. Product Picture of Viberzi
Figure 11. Product Picture of Lotronex
Figure 12. Product Picture of Other
Figure 13. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Type in 2023
Figure 14. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Market Share by Type (2019-2024)
Figure 15. Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumed in Hospitals Pharmacy
Figure 16. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market: Hospitals Pharmacy (2019-2024) & (K Units)
Figure 17. Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumed in Retail Pharmacy
Figure 18. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market: Retail Pharmacy (2019-2024) & (K Units)
Figure 19. Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumed in Other
Figure 20. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market: Other (2019-2024) & (K Units)
Figure 21. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Sales Channel (2023)
Figure 22. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Market Share by Sales Channel in 2023
Figure 23. Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market by Company in 2023 (K Units)
Figure 24. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Company in 2023
Figure 25. Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Market by Company in 2023 ($ Million)
Figure 26. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Market Share by Company in 2023
Figure 27. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Geographic Region (2019-2024)
Figure 28. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Market Share by Geographic Region in 2023
Figure 29. Americas Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales 2019-2024 (K Units)
Figure 30. Americas Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue 2019-2024 ($ Millions)
Figure 31. APAC Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales 2019-2024 (K Units)
Figure 32. APAC Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue 2019-2024 ($ Millions)
Figure 33. Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales 2019-2024 (K Units)
Figure 34. Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue 2019-2024 ($ Millions)
Figure 35. Middle East & Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales 2019-2024 (K Units)
Figure 36. Middle East & Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue 2019-2024 ($ Millions)
Figure 37. Americas Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Country in 2023
Figure 38. Americas Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Market Share by Country in 2023
Figure 39. Americas Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Type (2019-2024)
Figure 40. Americas Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Sales Channel (2019-2024)
Figure 41. United States Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Growth 2019-2024 ($ Millions)
Figure 42. Canada Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Growth 2019-2024 ($ Millions)
Figure 43. Mexico Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Growth 2019-2024 ($ Millions)
Figure 44. Brazil Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Growth 2019-2024 ($ Millions)
Figure 45. APAC Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Region in 2023
Figure 46. APAC Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Market Share by Regions in 2023
Figure 47. APAC Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Type (2019-2024)
Figure 48. APAC Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Sales Channel (2019-2024)
Figure 49. China Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Growth 2019-2024 ($ Millions)
Figure 50. Japan Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Growth 2019-2024 ($ Millions)
Figure 51. South Korea Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Growth 2019-2024 ($ Millions)
Figure 52. Southeast Asia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Growth 2019-2024 ($ Millions)
Figure 53. India Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Growth 2019-2024 ($ Millions)
Figure 54. Australia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Growth 2019-2024 ($ Millions)
Figure 55. China Taiwan Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Growth 2019-2024 ($ Millions)
Figure 56. Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Country in 2023
Figure 57. Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Market Share by Country in 2023
Figure 58. Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Type (2019-2024)
Figure 59. Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Sales Channel (2019-2024)
Figure 60. Germany Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Growth 2019-2024 ($ Millions)
Figure 61. France Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Growth 2019-2024 ($ Millions)
Figure 62. UK Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Growth 2019-2024 ($ Millions)
Figure 63. Italy Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Growth 2019-2024 ($ Millions)
Figure 64. Russia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Growth 2019-2024 ($ Millions)
Figure 65. Middle East & Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Country in 2023
Figure 66. Middle East & Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Market Share by Country in 2023
Figure 67. Middle East & Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Type (2019-2024)
Figure 68. Middle East & Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Sales Channel (2019-2024)
Figure 69. Egypt Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Growth 2019-2024 ($ Millions)
Figure 70. South Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Growth 2019-2024 ($ Millions)
Figure 71. Israel Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Growth 2019-2024 ($ Millions)
Figure 72. Turkey Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Growth 2019-2024 ($ Millions)
Figure 73. GCC Country Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Growth 2019-2024 ($ Millions)
Figure 74. Manufacturing Cost Structure Analysis of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs in 2023
Figure 75. Manufacturing Process Analysis of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs
Figure 76. Industry Chain Structure of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs
Figure 77. Channels of Distribution
Figure 78. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Forecast by Region (2025-2030)
Figure 79. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Market Share Forecast by Region (2025-2030)
Figure 80. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share Forecast by Type (2025-2030)
Figure 81. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Market Share Forecast by Type (2025-2030)
Figure 82. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share Forecast by Sales Channel (2025-2030)
Figure 83. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Market Share Forecast by Sales Channel (2025-2030)
